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osting by EAbstract Background: Over recent years it has become apparent that the hepatocyte mitochondrion
functions both as a cause and as a target of liver injury. Resultant dysfunction of mitochondria yields
deﬁcient oxidative phosphorylation, increased generation of reactive oxygen species, impairment of
other metabolic pathways and activation of both necrotic and apoptotic pathways of cellular death.
Methods: This study was conducted on 26 children and adolescents with chronic liver disease who
presented to or were following up in the Pediatric Hepatology Clinic, Children’s Hospital, Ain-Shams
University. They were divided into three groups according to the aetiology of liver disease (GI =
patients with Wilson’s disease (WD), GII = patients with chronic hepatitis C, GIII = patients with
chronic liver disease other thanWilson’s and chronic hepatitis C). Ultrasound-guided gun liver biopsies
were performed, under local anaesthesia for all the 26 patients, using a modiﬁed 18-gauge truecut
needle. Two liver biopsy cores were taken from each patient. One for light and electron microscopic
examinations and the other was immediately immersed in liquid nitrogen to be frozen and used for
studying mitochondrial DNA deletions by PCR.Tomanbay St., Hammamat,
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144 R.M. Shawky et al.Results: Liver steatosis was higher in the group of patients with Wilson’s disease and other liver dis-
ease. Electron microscopic examination of the mitochondria revealed signiﬁcant mitochondrial pleo-
morphism in patients with Wilson’s disease and patients with chronic hepatitis C infection. Enlarged
mitochondriawere found to bemore prevalent among patientswith chronic hepatitis C infection. Three
of our patients (11.53%) had mitochondrial DNA deletions. We developed scoring system for mito-
chondrial affection in our patients, 7 patients (32%) were considered to have mild mitochondrial affec-
tion, 9 patients (41%) had moderate mitochondrial affection, while 6 patients (27%) had severe
mitochondrial affection. Four of the studied patients had no mitochondrial affection.
Conclusion: Mitochondria affection is common in chronic liver disease. This mitochondrial affection
might be responsible for some of the chronic liver disease manifestation such as easy fatiguability and
steatosis.
 2010 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Chronic hepatitis is an ongoing injury to the liver cells which
lasts for longer than 6 months. It may be caused by many fac-
tors such as: viruses (B, C and D), drugs, autoimmune disease,
metabolic disease and other disorders. The hepatitis C virus
(HCV) is one of the most important causes of chronic liver dis-
ease. It accounts for 60–70% percent of chronic hepatitis cases,
and up to 50% of cirrhosis, end-stage liver disease and liver
cancer [1]. An inherited defect in the metabolism of copper is
known to cause chronic hepatitis (copper-associated hepati-
tis/copper toxicosis) [2].
Mitochondrial medicine is a new and rapidly developing
medical subspeciality. Researchers discovered that mitochon-
dria have their own DNA or ‘‘blue print’’ (mtDNA), which
is different than the nuclear DNA (nDNA) found in the cell’s
nucleus. Mitochondria are the power house of the cell being
responsible for processing oxygen and converting substances
from the foods we eat into energy for the essential cell func-
tions [3]. Mitochondrial and metabolic medical conditions
are now referred to as mitochondrial cytopathies, which actu-
ally include more than 40 different identiﬁed diseases that have
different genetic features [4].
Hepatic involvement is a common feature in childhood
mitochondrial hepatopathies particularly in the neonatal peri-
od, and may manifest as neonatal acute liver failure, steatohep-
atitis, cholestasis, or cirrhosis with chronic liver failure of
insiduous onset. In recent years, speciﬁc molecular defects
(mutations in nuclear genes such as SCO1, BCS1L, POLG,
DGUOK and MPV17 and the deletion or rearrangement of
mitochondrial DNA) have been identiﬁed, with the promise
of genetic and prenatal diagnosis [5]. Studies assessing mito-
chondrial function and structure in livers from humans with
chronic liver disease, including liver cirrhosis, revealed a variety
of alterations in comparison with normal subjects. Depending
on the aetiology of chronic liver disease, the function of electron
transport chain and/or ATP synthesis was found to be
impaired, leading to decreased oxidative metabolism of various
substrates and to impaired recovery of the hepatic energy state
after a metabolic insult. The most important strategies to main-
tain an adequate mitochondrial function per liver are mito-
chondrial proliferation and increase in the activity of critical
enzymes or in the content of cofactors per mitochondrion [6].
Hepatocyte mitochondrion functions are a cause as well as
a target of liver injury [7]. In primary disorders, mitochondrial
defect is the primary cause of liver disease often producingfatal hepatic failure in infancy or childhood. In secondary dis-
orders, insult to mitochondria is caused by either a gene defect
that affects non-mitochondrial proteins or by an exogenous in-
jury to mitochondria [8].
Treatment of these disorders is currently empirical involv-
ing agents that may improve the redox status of mitochondria,
promote electron ﬂow, or act as mitochondrial antioxidants.
Liver transplantation has occasionally been successful in
patients who lack other systemic involvement [9].
The objective of the present study is the assessment of mito-
chondria in chronic liver disease among Egyptian children and
adolescents through studying their morphology by light
microscopy, electron microscopy and the deletion of mito-
chondrial DNA.
2. Subjects and methods
This study included 26 children and adolescents with chronic
liver disease who presented to or were following up in the pedi-
atric hepatology clinic, children’s Hospital, Ain-Shams Univer-
sity in the period from 2006 to 2009. They were 14 males and 12
females with male to female ratio 1.6:1. Their age ranged from
3 months to 17 years with a mean age of 9 ± 3.8 years.
2.1. Inclusion criteria
Children and adolescents eligible to be included were:
1. Patients with chronic HCV infection, Wilson’s disease or
any other chronic liver disease (diagnosed clinically, bio-
chemically and/or histologically).
2. Patients having single liver pathology.
3. Recently diagnosed patients who did not start treatment yet
and had a clear deﬁnite diagnosis.2.2. Exclusion criteria
Children and adolescents who were excluded were:
1. Patients who have started treatment.
2. Patients who presented with acute liver disease.
3. Patients suffering from more than one pathology directly
affecting the liver (e.g., thalassemics).
4. Patients who proved to have primary mitochondrial
disease.
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drugs that might affect mitochondria.
6. Patients having coagulopathy till being controlled.
 Patients were classiﬁed into three groups based on the
aetiology of liver disease:
Group I: Patients with Wilson’s disease (11 patients).
Group II: Patients with chronic hepatitis C (6 patients).
Group III: Patients with chronic liver diseases other than
Wilson’s and chronic hepatitis C (9 patients), 2
with type 1 diabetes, 2 with glycogen storage dis-
ease, 2 with lipid storage disease, one with type I
autoimmune hepatitis, one patient with congeni-
tal hepatic ﬁbrosis and one patient with Budd-
chiari syndrome.2.3. Methods
All included patients were chosen after doing the following:
(A) Baseline assessment which included:
I. Full history taking: with special emphasis on duration
of liver disease, symptoms suggestive of advanced liver
disease (gastro-intestinal bleeding, jaundice, ascites, neu-
rological manifestations, fatigue, any other system affec-
tion, etc.).
II. Thorough clinical examination with special emphasis on
signs of chronic liver disease (jaundice, clubbing, spider
naevi, edema, distended abdominal wall veins, etc.),
abdominal examination (ascites, liver and spleen size),
signs of hyperdynamic circulation, and full neurological
examination.
III. Investigations: complete blood picture, liver functions
tests which included; serum ALT, AST, alkaline phos-
phatase, total bilirubin, direct bilirubin, albumin and
prothrombin time (INR), HCV antibody, HCV RNA
by PCR for patients with positive HCV-antibody, serum
ceruloplasmin, abdominal doppler U/S with special
emphasis on size of liver and spleen, texture of liver,
portal circulation, presence or absence of collaterals
and slit lamp examination of the eye for Kayser Fleisher
ring.2.3.1. Liver biopsy
Ultrasound-guided liver biopsies were performed, under local
anaesthesia for all the 26 patients, using a ultrasound guided
modiﬁed 18-gauge truecut needle. Two liver biopsy cores were
taken from each patient. One for light and electron micro-
scopic examinations and the other core was immediately
immersed in liquid nitrogen to be frozen and used for studying
mitochondrial DNA by PCR.2.3.2. Light microscopy
Liver biopsy specimens were ﬁxed in 10% buffered formalin
and embedded in parafﬁn. Six serial sections (thickness,
4–5 lm) were cut and stained with haemotoxylin-eosin and
Van Gieson stains. Histological ﬁndings and ﬁbrosis degree
were scored according to the numerical scoring system by
Knodell et al. [10]. Histological ﬁndings were blindly inter-
preted by a senior histopathologist.2.3.3. Electron microscopy
An aliquot of liver biopsy specimen was ﬁxed in 0.5% glutar-
aldehyde plus 4% paraformaldehyde, then postﬁxed in os-
mium tetroxide. The liver biopsy specimen was then
dehydrated in graded alcohol and embedded in araldite.
After uranyl acetate and lead citrate staining the thin sections
were observed with a Philips 400 T transmission electron
microscopy. Histological ﬁndings were interpreted by a senior
histopathologist.2.3.4. Mitochondrial DNA PCR
All the DNA samples were extracted from liver biopsies (fro-
zen section) and whole blood (10 ml heparinized whole blood)
according to Goto et al. [11]. We quantitated mitochondrial
DNA for deletion by the method described by Goto [12].
Approximately 2 lg DNA aliquot from patient and from
one control (wild DNA and plasmid with known mitochon-
drial DNA deletion) were used in two polymerase chain reac-
tions each amplifying a part of the mitochondrial DNA
sequence; the ﬁrst reaction amplifying 11.2 kb while the sec-
ond reaction amplifying 5.3 kb, to check the whole mitochon-
drial DNA sequencing for any deletions. Long PCR was done
in each reaction using forward and reverse primers. The ﬁrst
set P1001, P1004, covered the longer portion of mitochondrial
DNA, while the second set P1003, P5204 covered the smaller
portion of mitochondrial DNA. The template DNA from all
patients was ampliﬁed using thermal cycler (PJ 9600) (Perkin
Elmer). The ampliﬁed DNA fragments were electrophoreti-
cally checked on 1% agarose gel to check for the deleted
DNA.2.3.5. Statistical analysis
The results of light microscopic, electron microscopic examina-
tion and mitochondrial DNA-PCR assessment of the three
groups were tabulated and statistically analyzed using personal
computer with SPSS software package. We used repeated mea-
sures ANOVA, Pearson v2-test and Z-test. A cut point of 0.05
was used to designate statistical signiﬁcance and 0.01 to desig-
nate high signiﬁcance.
For inclusion in the study, an informed written consent was
obtained from the children’s guardians. The study protocol
was approved by the hospital’s ethical committee.3. Results
The results of present study could be summarized in the fol-
lowing points:3.1. Results of light microscopy
Results of light microscopic examination of the liver biopsy are
shown in Tables 1a and b. The number of patients with dis-
turbed hepatic architecture is signiﬁcantly higher in patients
with Wilson’s disease than in patients with chronic hepatitis
C or patients with other chronic liver disease. As regards por-
tal tract ﬁbrosis or inﬂammation, disruption of the limiting
plate, hepatocyte ballooning, liver cirrhosis, micro-vesicular
steatosis, macro-vesicular steatosis, there is insigniﬁcant statis-
tical difference between the three groups.
Table 1a Comparison between patients with Wilson’s disease (WD) vs. patients (HCV) as regards light microscopic ﬁndings.
Light microscopic ﬁndings Group N % Chi-square
X2 P-value Signiﬁcance
Disturbed hepatic architecture Wilson’s 8/11 72.73 0.243 0.62 P> 0.05
HCV 1/6 16.67 Non-signiﬁcant
Portal tract ﬁbrosis Wilson’s 9/11 81.82 2.941 0.230 P> 0.05
HCV 4/6 66.67 Non-signiﬁcant
Portal tract inﬂammation Wilson’s 8/11 72.73 2.235 0.327 P> 0.05
HCV 6/6 100.00 Non-signiﬁcant
Disruption of the limiting plate Wilson’s 5/11 45.45 0.118 0.943 P> 0.05
HCV 3/6 50.00 Non-signiﬁcant
Hepatocyte ballooning Wilson’s 11/11 100.00 4.156 0.041 P< 0.05
HCV 4/6 66.67 Signiﬁcant
Liver cirrhosis Wilson’s 6/11 54.55 2.300 0.129 P< 0.05
HCV 1/6 16.67 Non-signiﬁcant
Micro-vesicular steatosis Wilson’s 6/11 54.55 2.059 0.560 P> 0.05
HCV 2/6 33.33 Non-signiﬁcant
Macro-vesicular steatosis Wilson’s 2/11 18.18 4.353 0.113 P> 0.05
HCV 0/6 0.00 Non-signiﬁcant
Comment: Disturbed hepatic architecture and liver cirrhosis, were more common in WD>HCV. Portal tract inﬂammation was more in
HCV>WD, steatosis (micro-vesicular and macro-vesicular) more in WD.
Table 1b Comparison between the patients with Wilson’s disease and patients with hepatitis C virus (HCV) versus patients with other
chronic liver diseases as regards light microscopic ﬁndings.
Light microscopic ﬁndings Group N % Chi-square
X2 P-value Signiﬁcance
Disturbed hepatic architecture Wilson’s & HCV 9/17 52.94 4.462 0.216 P> 0.05 Non-signiﬁcant
Other CLD 7/9 77.78
Portal tract ﬁbrosis Wilson’s & HCV 13/17 76.47 0.58 0.445 P> 0.05 Non-signiﬁcant
Other CLD 8/9 88.89
Portal tract inﬂammation Wilson’s & HCV 14/17 82.35 11.846 0.008 P< 0.01 Highly signiﬁcant
Other CLD 5/9 55.56
Disruption of the limiting plate Wilson’s & HCV 8/17 47.06 3.231 0.357 P> 0.05 Non-signiﬁcant
Other CLD 3/9 33.33
Hepatocyte ballooning Wilson’s & HCV 15/17 88.24 0.193 0.660 P> 0.05 Non-signiﬁcant
Other CLD 8/9 88.89
Liver cirrhosis Wilson’s & HCV 7/17 41.18 3.846 0.279 P> 0.05 Non-signiﬁcant
Other CLD 6/9 66.67
Microvesicular steatosis Wilson’s & HCV 8/17 47.06 2.615 0.455 P> 0.05 Non-signiﬁcant
Other CLD 4/9 44.44
Macrovesicular steatosis Wilson’s & HCV 2/17 11.76 16.154 0.001 P< 0.01 Highly signiﬁcant
Other CLD 3/9 33.33
Table 2a Comparison of patients with Wilson’s disease versus patients with HCV as regards electron microscopic ﬁndings.
Electron microscopic ﬁndings Group N % Chi-square
X2 P-value Signiﬁcance
Mitochondrial pleomorphism Wilson’s
HCV
10/11
6/6
90.91
100.00
7.176 0.028 P< 0.05 Signiﬁcant
Mitochondrial enlargement Wilson’s
HCV
7/11
6/6
63.64
100.00
0.824 0.662 P>0.05 Non-signiﬁcant
Mitochondrial dense metrical granules Wilson’s
HCV
8/11
5/6
72.73
83.33
6.294 0.098 P> 0.05 Non-signiﬁcant
Degeneration of mitochondrial cristae Wilson’s
HCV
5/11
1/6
45.45
16.67
1.98 0.159 P< 0.05 Signiﬁcant
Widening of mitochondrial inter-crystal space Wilson’s
HCV
3/11
0/6
27.27
0.00
2.235 0.327 P> 0.05 Non-signiﬁcant
Lysosomal enlargement Wilson’s
HCV
5/11
1/6
45.45
16.67
1.409 0.235 P> 0.05 Non-signiﬁcant
Dilatation and vesiculation of the endoplasmic reticulum Wilson’s
HCV
3/11
5/6
27.27
83.33
4.898 0.27 P< 0.05 Signiﬁcant
N.B. The electron microscopy of one patient (who had lipid storage disease and severe cachexia) could not be obtained as the biopsy was very
small revealed only portal tract and the general condition of the patient did not allow another biopsy.
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Table 2b Comparison of patients with Wilson’s disease and patients with HCV versus patients with other CLD as regards electron
microscopic ﬁndings.
Electron microscopic ﬁndings Group N % Chi-square
X2 P-value Signiﬁcance
Mitochondrial pleomorphism Wilson’s and HCV
Other CLD
16/17
4/8
94.12
50.00
13.520 0.001 P< 0.01 Highly signiﬁcant
Mitochondrial enlargement Wilson’s and HCV
Other CLD
13/17
4/8
76.47
50.00
0.040 0.841 P> 0.05 Non-signiﬁcant
Mitochondrial dense metrical granules Wilson’s and HCV
Other CLD
13/17
3/8
76.47
37.50
10.040 0.018 P< 0.05 Signiﬁcant
Degeneration of mitochondrial cristae Wilson’s and HCV
Other CLD
6/17
0/8
35.29
0.00
1.520 0.468 P> 0.05 Non-signiﬁcant
Widening of mitochondrial inter-crystal space Wilson’s and HCV
Other CLD
3/17
1/8
17.65
12.50
0.107 0.74 P> 0.05 Non-signiﬁcant
Lysosomal enlargement Wilson’s and HCV
Other CLD
6/17
1/8
35.29
12.50
8.120 0.044 P< 0.05 Signiﬁcant
Dilatation and vesiculation of the endoplasmic
reticulum
Wilson’s and HCV
Other CLD
8/17
4/8
47.06
50.00
0.080 0.961 P> 0.05 Non-signiﬁcant
Comment: Mitochondrial E/M changes were more common in WD and HCV than other CLD.
Table 3 The mitochondrial affection scoring system.
Degree of
mitochondrial
aﬀection
Number of aﬀected
mitochondrial
parameters
Number of
aﬀected patients with
chronic liver disease
Mild 1–2 7/22 (32%)
Moderate 3 9/22 (41%)
Severe 4–5 6/22 (27%)
66.60%
66.60%
28.50%
Mild
Moderate
Severe
Figure 1 The presence of hepatic steatosis among patients with
different degrees of mitochondrial affection.
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Results of electron microscopy of liver biopsy are shown in
Tables 2a and b. Twenty of the studied patients (80%) had
mitochondrial pleomorphism. The number of chronic hepati-
tis C patients with mitochondrial pleomorphism is signiﬁ-
cantly higher than that of patients with Wilson’s disease or
of patients with other chronic liver disease. There is insignif-
icant difference among the three groups as regards the num-
ber of patients.Table 4 Relation of degree of mitochondrial affection to hepatic st
Degree of mitochondrial Hepatic steatosis
Present Absent T
No. % No. % N
Mild 2/7 28.57 5/7 71.5 7
Moderate 6/9 66.6 3/9 33.4 9
Severe 4/6 66.6 2/6 33.4 6
Although there was no statistical difference between the three studied grou
is an increase in severity with increase frequency of steatosis.
N.B.: Four of the studied patients had no mitochondrial affection.3.3. Result of mitochondrial PCR
Mitochondrial DNA deletions was found in three patients
(12%) (two with Wilson’s disease and one with lipid storage
disease).eatosis.
Chi square value P-value
otal
o. %
/22 31.8 1.281 0.257
P> 0.05 Non-signiﬁcant/22 40.9
/22 27.2
ps (classiﬁed according to degree of mitochondrial affection) yet there
148 R.M. Shawky et al.We developed a scoring system for mitochondrial affection
in our patients depending on the degree of the previously men-
tioned ultra-structural mitochondrial changes. Four of the
studied patients had no mitochondrial affection (see Fig. 1
and Tables 3 and 4).4. Discussion
Mitochondria are important cellular organelles responsible for
energy production through oxidative phosphorylation (OX-
PHOS). Mitochondrial dysfunction yields deﬁcient oxidative
phosphorylation, increased generation of reactive oxygen spe-
cies (ROS), accumulation of hepatocyte lipid, impairment of
other metabolic pathways and activation of both apoptotic
and necrotic pathways of cellular death [13]. The only DNA
outside the nucleus is the mitochondrial DNA, it is character-
ized by its high mutability and by being only maternally inher-
ited [14]. Mitochondrial disorders were once regarded as
neuromuscular diseases, however 33–56% of patients with
mitochondrial disorders have non-neuromuscular manifesta-
tions at presentation [15]. Sokol and Treem [16] have proposed
a classiﬁcation scheme for mitochondrial hepatopathies into
primary and secondary hepatopathies. In primary disorders,
mitochondrial defect is the primary cause of liver disease. In
the secondary disorders hepatic mitochondria undergo injury
or dysfunction caused by another pathologic process [17],
including diseases of uncertain aetiology (e.g. Reye’s syn-
drome), exposure to endogenous and exogenous toxins, drugs
(such as nucleoside analogues), or metals, and other conditions
in which mitochondrial oxidative injury or abnormal electron
transport may be involved (e.g. cholestasis, NASH) [15,16].
Among our 26 chronic liver disease patients 22 patients
(84.6%) showed evidence of mitochondrial affection in the
form of ultra-structural mitochondrial morphological changes,
steatosis, and or mitochondrial DNA deletions. As all our pa-
tients were with a well deﬁned aetiological diagnosis thus, the
mitochondrial affection of the patients could not be explained
by a primary mitochondrial disease; all were secondary mito-
chondrial affection. We divided our patients into three groups
(Group I: patients with Wilson’s disease, Group II: patients
with chronic hepatitis C, Group III: patients with chronic liver
disease other than Wilson’s and chronic hepatitis C). Clinically
there were no differences between the three groups except in
the frequency of hepatomegaly which was higher in Wilson’s
disease patients (10 out of 11, 99.9%). This hepatomegaly
could be explained by the early glycogen deposition and fatty
inﬁltration of the liver in WD [18]. Pathologically cirrhosis and
hepatic architecture disturbance were higher among Group I
and Group III (8 out of 11, 72.73%) (7 out of 9 77.78%), com-
pared to patients with Group II (1 out of 6, 16.6%, respec-
tively). This could be explained based on the natural history
of liver affection in Wilson’s disease that usually peaks at ages
10–13 years [19]. Irrespective of the initial symptoms, almost
all patients will have some evidence of cirrhosis on liver biopsy
reﬂecting the response to years of hepatic copper accumulation
before clinical symptoms [20]. In our study chronic hepatitis C
patients were freshly diagnosed with short disease duration,
thus explaining the low frequency of cirrhosis in these patients
(6–12 months from diagnosis). This was in consistency with
other studies held by Kage et al. [21] who studied the pathol-
ogy of chronic hepatitis C in children and they reported nocase of cirrhosis and only 3.9% of children had architectural
distortion and bridging ﬁbrosis (mean duration of infection
in this study was 2–6 years), and that of Goodman et al. [22]
who published that inﬂammation, ﬁbrosis, steatosis and cir-
rhosis were mild, in HCV infected children. They added that,
there is a positive correlation of inﬂammation with the dura-
tion of infection.
Mitochondrial affection in these three groups of patients
showed some variabilities. All 11 patients with Wilson’s dis-
ease had morphological evidence of mitochondrial affection
in the form of mitochondrial pleomorphism in 10 out of 11
(90.91%), mitochondrial enlargement in 7 out of 11
(63.64%), mitochondrial dense metrical granules in 8 out of
11 (72.73%), degeneration of mitochondrial cristae in 5 out
of 11 (45.45%) and widening of mitochondrial inter-crystal
space in 3 out of 11 (27.27%). Also steatosis (micro-vesicular
and macro-vesicular) was present in 6 out of 11 of WD pa-
tients. Wilson’s disease is caused by diverse mutation of nucle-
ar gene encoding a copper-transporting ATPase. Decreased
elimination of copper into the bile causes progressive accumu-
lation of copper into hepatocytes. Mitochondrial involvement
in Wilson’s disease has been implicated since the early observa-
tion by Stenlieb et al. [23] of abnormal mitochondrial mor-
phology so characteristic of this disorder of copper
metabolism. Changes include decreased matriceal density en-
larged inter-membranous spaces, dilatation and vacuolization
of cristae, crystalline inclusion and vacuoles in the matrix. This
was directly proportionate to the age and was more prevalent
among patients with hepatic variety than in patients with the
neurological variety. Copper selectively accumulates within
mitochondria during copper overload leading to mitochon-
drial dysfunction and increasing mitochondrial reactive oxy-
gen species (ROS) production. Mitochondrial ROS target
proteins, and patients with Wilson’s disease have decreased
activity of respiratory chain complexes, which may further in-
crease mitochondrial oxidative pathway [24]. Sokol and Nar-
kewicz [25] mentioned that in the early stages of Wilson’s
disease, hepatocellular mitochondria are pleomorphic and
abnormally large. This is because patients with Wilson’s dis-
ease have decreased activity of respiratory chain complex.
Findings are consistent with ﬁndings of Abdel Ghaffar et al.
[26] who studied Wilson’s disease in Egyptian children. They
found that 85.7% of their patients with Wilson’s disease
had mitochondrial alteration in form of pleomorphism in
shape and size, with the presence of giant forms and ﬁnely
granular and coarse electron dense material. These results were
strengthened by the ﬁndings of Brewer [27], who described
the abnormal mitochondrial morphology characteristic of
Wilson’s disease which included, intermembranous space dila-
tion and vacuolization of cristae, crystalline inclusions and
vacuoles in the matrix. Also he documented disappearance
of cristea and widening of the inter-crystal space of the hepatic
mitochondria. Gu et al. [28] who studied oxidative phosphor-
ylation in Wilson’s disease and showed evidence of severe
mitochondrial dysfunction in livers of patients with Wilson’s
disease. In their study, enzyme activities were decreased as
follows: complex I by 62%, complex II + III by 52%, com-
plex IV by 33% and aconitsae by 71%. On the contrary, they
reported that high copper concentrations found in the liver of
the studied patients with primary biliary (PBC) and primary
sclerosing cholangitis (PSC) were not associated with the
mitochondrial fraction. Mitochondrial respiratory chain func-
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supporting the suggestion that it is the intra-mitochondrial
localization of copper which results in deﬁciency of these en-
zymes in Wilson’s disease. They proposed that WD protein
might function as a copper transporter at both the trans-Golgi
network and at the mitochondrial membrane, and mutations
in ATP7B gene may cause mitochondrial copper overload
through defective export. In our study lysosomal enlargement
was found in 5 out of 11 (45.4%) patients with Wilson’s dis-
ease compared to only two patients in each of other two
groups. This lysosomal enlargement could be explained by
the accumulation of copper within the lysosomes and denotes
later stages of the disease as Liu et al. [29] studied copper dis-
tribution inside and outside lysosomes in the Wilson’s disease.
They found that in the early stage of hepatolenticular disease,
copper is accumulated outside lysosome, which is paralleled
with increase of metallothionein-like protein (copper and sul-
fur-binding protein). With the development of the disease,
more copper is deposited inside lysosome than outside lyso-
some. They concluded that the up-regulation expression of
copper and sulfur-binding protein and copper accumulation
in lysosomes may play an important role in lowering the
ATP-7B gene mutation-included toxic effects of free copper
on the cell.
All six patients with hepatitis C virus (HCV) in our study
also had mitochondrial morphological changes in the form
of mitochondrial pleomorphism in 6 out of 6 (100%), mito-
chondrial enlargement in 6 out of 6 (100%), mitochondrial
dense metrical granules in 5 out of 6 (83.3%), degeneration
of mitochondrial cristae in 1 out of 6 (16.67%). None had wid-
ening of mitochondrial inter-crystal space, also micro-vesicular
steatosis was present in 2 out of 6 HCV patients (33.3%).
These ﬁndings were supported by that of Calza et al. [30]
who reported that, mitochondrial alterations were demon-
strated in HCV infected subject and the most frequent alter-
ation was mitochondrial pleomorphism. Barbaro et al. [31]
found enlarged irregular mitochondria in 92% of studied pa-
tients with hepatitis C (genotype Ia). Barbaro et al. [32] also
reported that 25% of studied patients with hepatitis C infec-
tion had dense mitochondrial granules. This granules are osmi-
ophilic granules which are able to be involved in haemostasis
of calcium. Calza et al. [30] found reduction or loss of cristae
in (20.5%) of cases with HCV infection. In our study micro-
vesicular steatosis was detected in liver biopsy of 2 out of 6
(33.3%) with chronic hepatitis C patients. This is nearly in
agreement to the result of Zubair et al. [33] who observed
micro-vesicular steatosis in 21 out of 46 cases with hepatitis
C (HCV) virus infection. They reported that steatosis is a com-
mon histologic feature of chronic hepatitis C (CHC). This
complication of CHC may have implication on its long-term
prognosis. Steatosis can be explained by the ﬁndings of Salem
et al. [34] they documented enhanced lipid peroxidation in all
patients by assaying lipid peroxidation products in plasma
malondialdehyde (MDA). Another study held by Bortolotti
et al. [35] found that 27.5% of the studied 80 children with
chronic hepatitis C infection had steatosis. The mechanism
by which the hepatitis C virus (HCV) causes steatosis is un-
known. Ramalho [36] suggested that both host and viral fac-
tors may play an important role in its development. He
suggested a direct effect of certain viral sequence on the path-
ogenesis of hepatic steatosis. Okuda [37] studied the mitochon-
drial affection induced by hepatitis C core protein. They foundthat core protein also increased lipid peroxidation products
and induced antioxidant gene expression as well. A mitochon-
drial electron transport inhibitor prevented the core-induced
increase in ROS. A fraction of expressed core protein was
localized to the mitochondria and was associated with redistri-
bution of cytochrome C from mitochondrial to cytosolic frac-
tions. Therefore they concluded that hepatitis C has direct
effect on mitochondria. Another possible mechanism could
be drawn from the study of Barbaro et al. [38] in this study,
chronic hepatitis patients showed depletion of glutathione
(H-GSH, P-GSH and L-GSH). The value of P-GSH and
L-GSH were found to reﬂect directly the hepatic stores of
GSH. They proved an inverse correlation between GSH and
MDA that reﬂects an increase in lipid peroxidation in patients
with hepatitis C. They attributed this deﬁciency in glutathione
to increased free radical production as well as mitochondrial
dysfunction. It is essential also to mention the work of Badi-
zadegan et al. [39] who compared the histopathologic features
of liver in children and adults with hepatitis C virus infection.
They documented that steatosis is higher in adults (54–72%)
with chronic hepatitis C infection than in children (50%). This
was attributed to longer duration of disease. The ﬁnding of al-
tered mitochondrial structure in HCV-related liver disease
would help to explain the steatosis that is so prevalent in this
disease. These mitochondrial changes were found signiﬁcantly
more often in patients with genotype 1b than in patients with
genotype 2a/C or 3a. All mitochondrial alterations were asso-
ciated with a depletion of tissue glutathione store, a key cellu-
lar antioxidant. Collectively, the data suggest that genotype-
dependent mitochondrial alterations are a prominent feature
of liver cell injury by HCV [40].
Still in patients with other chronic liver disease mitochon-
drial affection was present but less frequently, while steatosis
was found in 66.6% of patients with either moderate or severe
mitochondrial affection, only 28.5% of patients with mild
mitochondrial affection had hepatic steatosis, thus relating ste-
atosis to the degree of mitochondrial affection. In secondary
steatohepatitis such as in Wilson’s disease, the vicious cycles
of hepatic lipogenesis and hepatic steatosis are further aggra-
vated by the causative disease itself. Wilson’s disease increase
ROS formation, ROS may oxidize fat deposits, releasing lipid
peroxidation products that damage mitochondrial DNA and
proteins to partially block the ﬂow of electrons along the respi-
ratory chain, thus further increasing mitochondrial ROS for-
mation. ROS may also deplete antioxidants and cause the
formation of tumor necrosis factor-a (TNF-a), 2 effects that
may further impair the ﬂow of electrons and increase mito-
chondrial ROS formation leading to steatosis and so on. An-
other evidence of subcellular level of affection in hepatitis C
is the disruption in rough endoplasmic reticulum. This is con-
sistent with ﬁndings of Barbaro et al. [32] who reported dilated
vesiculated endoplasmic reticulum in 64% of the examined pa-
tients with hepatitis C virus (genotype 1-a). Also Tardif et al.
[41] documented that hepatitis C virus (HCV) gene expression
disrupts normal endoplasmic reticulum (ER) functions and in-
duce ER stress. ER stress results from accumulation of un-
folded or misfolded proteins in the ER.
In our study mitochondrial DNA deletion was found in
three patients (11.5%) (two with Wilson’s disease (7.69%)
and one with lipid storage disease (3.84%). The two patients
with Wilson’s disease were a 13 year old boy and a 12 year
old girl. Both were child C at time of presentation (both
150 R.M. Shawky et al.had ascites, hypoalbuminemia below 2.5 g/dl and prolonged
prothrombin time). The boy had some neurological manifesta-
tions ofWilson’s disease (mask like face, rigidity, salivations but
no involuntarymovements). They both had positive kayser-Fle-
isher ring. Their liver biopsies revealed cirrhosis and marked
mitochondrial morphological changes. Both of them had other
affected sibs. Mansouri et al. [42] found that oxidant damage in
hepatic mitochondria also leads to deletions in mtDNA in
young adults with Wilson’s disease. Copper is a powerful pro-
oxidant that generates the hydroxyl radicals and other reactive
species. Copper forms Cu–DNA complexes, this reactive spe-
cies are generated close to DNA, making it an elective target.
Copper cause single strand breaks, double strand breaks, in-
tra-strand links between adjacent bases, oxidized bases, base
substitutions, as well as adducts between DNA. DNA strand
breaks can cause misannealing during replication, leading to
DNA deletions [43]. Our results revealed that the prevalence
of micro-vesicular steatosis seemed to be two times greater in
patients with mitochondrial DNA deletion than in those with-
out (2 of 2 vs. 4 of 9). However, these numbers were small
and not statistically signiﬁcant. This is in consistency with the
ﬁndings of Mansouri et al. [42] who reported close proportions
(3 of 8 vs. 1 of 8). Chinnery et al. [44] mentioned that, themother
of a proband with a mtDNA deletion is usually unaffected and
does not have mtDNA deletions in her tissues; however, excep-
tions occur. The risk to the sibs of a proband is usually extre-
mely low. Offspring of a female proband are usually not at
risk of inheriting the mutation. Prenatal testing is available on
a clinical basis, although interpretation of results is difﬁcult.
Emphasized by presence of mitochondrial DNA deletion in 3
of our patients, mitochondrial DNA deletion are not inherited
from mother to children, it may occur as a new events.
5. Conclusion
We thus conclude that secondary mitochondrial hepatopathy
occurs frequently in patients with chronic liver disease espe-
cially if it is due to Wilson’s disease or HCV infection. This
hepatopathy could be explained by aetiological agent (Copper
in the case of Wilson’s disease, HCV genome in the case of
HCV infection) but may also be compounded by the presence
of the cirrhosis in itself.
Conﬂict of interest
The authors declare that there is no conﬂict of interest.
References
[1] Jau-Shin Wu. Chronic hepatitis (deﬁnition) (Taiwan Medical
Network-TMN) Old Doc wu’Series posta; 1996; Revised 12, 2009.
[2] Manolaki N, Nikolopoulou G, Daikos GL, Panagiotakaki Eleni,
Tzetis M, Roma Eleftheria, et al.. Wilson disease in children:
analysis of 57 cases. J Pediatr Gastroenterol Nutr 2009;48(1):72–7.
[3] Treem WR, Sokol RJ. Disorders of the mitochondria. Semin
Liver Dis 1998;18(3):237–53.
[4] Lee WS, Sokol RJ. Liver disease in mitochondrial disorders.
Semin Liver Dis 2007;27(3):259–73.
[5] Lee WS, Sokol RJ. Mitochondrial hepatopathies: advances in
genetics and pathogenesis. Hepatology 2007;45:1555–6.
[6] Massimo Z, Stefano Di. Mitochondrial disorders. Brain
2004;127(10):2153–72. doi:10.1093/brain/awh259.[7] Bandyopadhyay SK, Dutta A. Mitochondrial hepatopathies. J
Assoc Physicians India 2005;53:973–8.
[8] Schapira AH. New mitochondrial disorders. J Neurol Neurosurg
Psychiatry 2002;72:144–9.
[9] http://my.clevelandclinic.org/disorders/Mitochondrial_Disease/
hic_Mitochondrial_Di.
[10] Knodell RG, Ishak KG, Block WC, et al.. Formulation, applica-
tion of numerical scoring system for assessing histological activity
in a symptomatic chronic active hepatitis. Hepatology 1991;4:431.
[11] Goto Y, Koga Y, Horai SU, Nonaka I. Detection of mitochon-
drial DNA. J Neurol Sci 1990(100):63–96.
[12] Goto Y. Detection of DNA encompassing the deletion junction of
mitochondrial genome. Biochem Biophys Res Commun
1996;1(222):215–9.
[13] Moslemi AR, Darin N. Molecular genetic and clinic aspects of
mitochondrial disorders in childhood. Mitochondrion 2007;7(4):
241–52.
[14] Schwartz M, Vissing J. Paternal inheritance of mitochondrial
DNA. N Engl J Med 2002;347:576–80.
[15] Munnich A, Rotig A, Chretien D, et al.. Clinical presentation of
mitochondrial disorders in childhood. J Inherit Metab Dis
1996;19:521–7.
[16] Sokol RJ, Treem WR. Mitochondrial hepatopathics. In: Suchy
FJ, Sokol RJ, Balistreri WF, editors. Liver disease in children.
Philadelphia: Lippincott. Williams & Wilkins; 2001. p. 787–810.
[17] Chinnery PF, Turnbull DM. Epidemiology and treatment of
mitochondrial disorders. Am J Med Genet 2001;06:94–101.
[18] Ettinger MJ. Hepatic copper metabolism. In: Zakim D, Boyer T,
editors. Hepatology textbook of liver disease, 3rd ed., vol. 80(3).
Philadelphia, Toronto, London, Montere, Sydney: W.B Saunders
Company; 2001. p. 554–61.
[19] Shah R, Piper MH. Wilson disease: emedicine gastroenterology;
2009. http://www.emedicine.com/med/topic2413.htm.
[20] Loudianos G, Gitlin JD. Wilson’s disease. Semin Liver Dis
2003;20(3):353–64.
[21] Kage M, Fujisawa T, Shiraki K, Tanaka T, Kimura A, et al..
Pathology of chronic hepatitis C in children. Hepatology 1997;26:
771–5.
[22] Goodman ZD, Makhlouf HR, Liu L, et al.. Pathology of chronic
hepatitis C in children: liver biopsy ﬁndings in the Peds-C Trail.
Hepatology 2008;47(3):836–43.
[23] Stenlieb I, Quintana N, Volenberg I, Schilsky ML. An array of
mitochondrial affection in the hepatocytes of long-Evans Cinna-
mon rats. Hepatology 1995;22(6):1782–7.
[24] Schapira AH. Primary and secondary defects of mitochondrial
respiratory chain. J Inherit Metab Dis 2002;25(3):207–14.
[25] Sokol RJ, Narkewicz MR. Copper and iron storage disorders. In:
Suchy FJ, Sokol RJ, Balistrei WF, editors. Liver disease in
children. 2nd ed.. Lippincott William & Wilkins; 2001.
[26] Abdel Ghaffar TY, El Monaiery MS, Badr SH, Abdel Ghaffar
AY, Seif E. Wilson’s disease in Egyptian children: clinical,
biochemical, histological and ultra-structural characterization.
Egypt J Pediatr 1998;15(30):433–50.
[27] Brewer GJ. Recognition diagnosis and management of Wilson’s
disease. Proc Soc EX Bio Med 2000;223:39–46.
[28] Gu M, Copper JM, Butter P, Walker AP, Mistry PK, Dooley JS,
et al.. Oxidative–phosphorylation defects in liver of patients with
Wilson’s disease. Lancet 2000;356(9228):469–74.
[29] Liu W, Li JY, Jin J, Zuo J. Detection of distribution of copper
inside and outside of lysosomes in cultured hepatolenticular
degeneration ﬁbroblasts by electron prob X-ray microanalysis.
Hepatobiliary Pancreat Dis Int 2003;2(2):270–3.
[30] Calza L, Verucchi G, Biagetti C, Attard L, Costigliola P,
Manfredi R, et al. Liver mitochondrial abnormalities associated
with HCV-monoinfection, HIV–HCV-coinfection, and antiretro-
viral therapy in a chohort of 68 adult patients. In: 9th European
Aids Conference (EACS) 1st EACS Resistance and Pharmacology
Workshop, 2003, Warsaw, Poland.
Mitochondrial alterations in children with chronic liver disease 151[31] Barbaro G, Di Lorenzo G, Asti A, Ribersani M, Belloni G,
Grisorio B, Filice G, et al.. Hepatocellular mitochondrial alter-
ations in patients with chronic hepatitis C: ultrastructural and
biochemical ﬁndings. Am J Gastroenterol 1999;94(8):2198–205.
[32] Barbaro G, Di Lorenzo G, Soldini M, et al.. Hepatic glutathione
deﬁciency in chronic hepatitis C: quantitative evaluation in
patients who are HIV positive and HIV negative and correlation
with plasmic and lymphocytic concentrations and with the activity
of the liver disease. Am J Gastroenterol 2007;91:2569–73.
[33] Zubair A, Jamal S, Mubarik A. Morphometeric analysis of
hepatic steatosis in chronic hepatitis C infection. Saudi J Gastro-
enterol 2009;15:11–4.
[34] Salem M, El-serafy O, Abdel El-Rahman Hamouda, Arnaout H.
Lipid peroxidation in Wilson disease. Egypt J Med Human Genet
2001;2(1):33–41.
[35] Bortolotti F, Jara P, Diaz C, Vajro P, et al.. Post-transplantation
and community hepatitis C in childhood. J Pediatr 2008;124:
709–13.
[36] Ramalho F. Hepatitis C virus infection and liver steatosis.
Antiviral Res 2003;60(2):125–7.
[37] Okuda K. Chronic hepatitis. In: Okudak, Mitchel DG, Itai Y,
Ariyama J, editors. Hepatobiliary diseases: pathophysiology and
imaging. Canada and Australia: Blackwell Science USA; 2001. p.
103–18.[38] Barbaro G, Di Lorenzo G, Soldini M, et al.. Hepatic glutathi-
one deﬁciency in chronic hepatitis C. Quantitative evaluation in
patients who are HIV positive and HIV negative and correla-
tion with plasmic and lymphocytic concentrations and with the
activity of the liver disease. Am J Gastroenterol 1996;91:
2569–73.
[39] Badizadegan K, Ott MJ, Nelson SP, Perez-Atayde AR. Histopa-
thology of the liver in children with chronic hepatitis C viral
infection. Hepatology 1998;28(5):1416–23.
[40] Rust C, Gores G. Does hepatitis C cause liver injury by pathways
associated with mitochondrial dysfunction? Am J Gastroenterol
1999;94(8):2003–5.
[41] Tardif KD, Morik, Kaufman RJ, Siddiqui A. Hepatitis C virus
suppresses the IRE1-XBP1 pathway of the unfolded protein
response. J Biol Chem 2004;279(17):17158–64.
[42] Mansouri A, Graou I, Fromenty B, Berson A, et al.. Premature
oxidative aging of hepatic mitochondrial DNA. Gastroenterology
1997;113:599–605.
[43] Sokol R. Mechanisms of acute and chronic liver disease: impli-
cations for diagnosis, pathogenesis and treatment 2002. In:
AASLD Conference.
[44] Chinnery PF, DiMauro S, Shanske S, Schon EA, Zeviani M,
Mariotti C, et al.. Risk of developing a mitochondrial DNA
deletion disorder. Lancet 2004;364:592–6.
